Condensed Consolidated Statements of Cash Flows (USD $) In Thousands	9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010
Cash Flows from operating activities:
Net loss	$ (877)	$ (2,370)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	297	265
Share-based compensation expense	316	97
Gain on sale of asset	(28)	0
Sales discounts and provision for bad debts	28	(26)
Inventory valuation provision	20	(989)
Changes in operating assets and liabilities:
Accounts receivable	374	(1,166)
Inventory	(1,856)	26
Accounts payable	237	53
Accrued advertising and other allowances	(605)	653
Other operating assets and liabilities, net	(951)	374
Net cash used in operating activities	(3,045)	(3,083)
Cash flows from investing activities:
Capital expenditures	(288)	(146)
Proceeds from the sale of fixed assets	166	0
Acquisition of product license	0	(1,000)
Net cash flows used in investing activities	(122)	(1,146)
Cash flows from financing activities:
Proceeds from the exercise of stock options	0	133
Purchase of treasury stock	(449)	0
Net cash provided by (used in) financing activities	(449)	133
Net decrease in cash and cash equivalents	(3,616)	(4,096)
Cash and cash equivalents at beginning of period	8,232	12,801
Cash and cash equivalents at end of period	4,616	8,705
Supplemental disclosures of cash flow information:
Income taxes paid	0	0
Common stock issued to Phosphagenics Limited pursuant to a product license agreement	0	2,577
Common stock issued, in lieu of cash, as payment of accrued compensation	$ 294	$ 0